热门资讯> 正文
Purple Biotech GAAP EPADS of -$0.86
2025-11-14 21:12
- Purple Biotech press release (PPBT): Q3 GAAP EPADS of -$0.86.
- Cash position of $10.5 million as of September 30, 2025, with an anticipated cash runway into the first half of 2027, supporting the development of our CAPTN-3 technology platform through significant milestones.
More on Purple Biotech
- Purple Biotech announces receipt of Nasdaq minimum bid price notification
- Purple Biotech prices $6M public offering, $12M potential via warrants; shares down
- Seeking Alpha’s Quant Rating on Purple Biotech
- Historical earnings data for Purple Biotech
- Financial information for Purple Biotech
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
